Medicare coverage · Updated July 2026
Medicare GLP-1 Bridge
On July 1, 2026, Medicare started covering obesity GLP-1s for the first time. Eligible Part D members pay a flat $50 a month for Wegovy or Zepbound instead of a list price north of $1,000. Here is exactly who qualifies, what is covered, and what to do if you fall outside the lines.
The bridge in one screen
- •$50 flat copay per month on a covered obesity GLP-1, for eligible Medicare Part D enrollees.
- •Live since July 1, 2026 and scheduled to run through the end of 2027.
- •Covers Wegovy and Zepbound (KwikPen). It does not cover Ozempic or Mounjaro for weight loss.
- •Requires a qualifying BMI plus, in most bands, a weight-related condition. Prior authorization applies.
What the Medicare GLP-1 Bridge actually is
For years, Medicare was barred by statute from covering drugs used purely for weight loss. That is why a Medicare patient could get semaglutide for diabetes as Ozempic but not for obesity as Wegovy. The GLP-1 Bridge is the workaround: a time-limited program, running through December 31, 2027, that lets Part D plans cover the obesity-approved GLP-1s at a capped $50 monthly copay while a longer-term coverage model is finalized.
The important word is bridge. It is temporary, it runs through Medicare Part D, and it is narrowly scoped to obesity with specific BMI and health thresholds. If you are on Original Medicare with no Part D plan, there is nothing here to opt into yet.
Which GLP-1s the bridge covers
The single most common mistake is assuming this covers Ozempic. It does not. The bridge is tied to the obesity indication, so it follows the obesity-approved brands, not the diabetes ones.
| Brand | Molecule | In the bridge | Note |
|---|---|---|---|
| Wegovy | semaglutide (injection + oral tablet) | Covered | Obesity-approved. Included in the bridge. |
| Zepbound | tirzepatide (KwikPen) | Covered | KwikPen only. Single-dose vials and single-dose pens are not included. |
| Foundayo | orforglipron (oral) | Covered | Newer oral option. Confirm current status with your plan and Medicare.gov. |
| Ozempic | semaglutide | Not covered | Diabetes-approved, not obesity-approved. Not in the bridge. |
| Mounjaro | tirzepatide | Not covered | Diabetes-approved. Covered for diabetes under existing Part D rules, not the weight bridge. |
| Saxenda | liraglutide | Not covered | Older daily GLP-1. Not part of the bridge program. |
Covered-drug details reflect the program as reported in July 2026. The authoritative, current list is on Medicare.gov. Confirm specifics with your own plan before you count on coverage.
Who qualifies: the BMI thresholds
Eligibility tightens as BMI drops. At the top of the range, obesity alone is enough. Lower down, you need a documented weight-related condition to qualify.
Obesity at this threshold qualifies without an added condition.
A qualifying weight-related condition is required in this band.
The narrowest band, reserved for established cardiovascular or metabolic risk.
Framework as outlined by CMS for the GLP-1 Bridge. Individual plans apply prior authorization, so confirm your specific eligibility with your prescriber and plan.
How to get the $50 copay
- 1Confirm you are enrolled in a Medicare Part D plan. The bridge runs through Part D, not Original Medicare alone.
- 2Ask your prescriber to document your BMI and any qualifying condition, then submit a prior authorization (commonly via CoverMyMeds or fax).
- 3Once approved, fill a covered brand (Wegovy or the Zepbound KwikPen) at your pharmacy for the $50 copay.
- 4If your prior authorization is denied or you do not meet the criteria, look at the self-pay routes below.
Did not qualify? You still have options
The bridge leaves out a lot of people. You are outside it if any of these apply:
- –You are not enrolled in a Medicare Part D plan (the bridge runs through Part D).
- –Your only indication is type 2 diabetes. Diabetes GLP-1 coverage runs through existing Part D rules, not this weight-focused bridge.
- –You want a GLP-1 for obstructive sleep apnea or MASH (fatty liver). Those indications are outside the bridge.
- –You want Ozempic or Mounjaro specifically. The bridge uses the obesity-approved brands (Wegovy, Zepbound), not the diabetes brands.
- –You are under 65 and not on Medicare through a disability pathway.
If that is you, insurance is not the path, and the realistic affordable route is a self-pay telehealth program. A US-licensed clinician can prescribe compounded semaglutide or tirzepatide, commonly from around $129/mo, with no insurance and no in-person visit. It costs more than the $50 bridge copay but far less than a brand-name pen at full price.
Medicare GLP-1 Bridge questions
Does Medicare cover Wegovy in 2026?+
Yes, for eligible enrollees. Since July 1, 2026, the Medicare GLP-1 Bridge covers Wegovy (semaglutide) at a flat $50 monthly copay for Part D members who meet the BMI and condition thresholds. The program is scheduled to run through the end of 2027.
Does Medicare cover Zepbound in 2026?+
Yes, the Zepbound KwikPen is included in the bridge for eligible Part D enrollees at the $50 copay. Note that single-dose vials and single-dose pens are not part of the program, only the KwikPen presentation.
Does Medicare cover Ozempic for weight loss?+
No. Ozempic is approved for type 2 diabetes, not obesity, so it is not part of the GLP-1 Bridge and Medicare does not cover it for weight loss. The bridge instead covers the obesity-approved brands, Wegovy and Zepbound. If you are seeking Ozempic specifically for weight, a self-pay telehealth program is usually the realistic route.
How much is the GLP-1 Bridge copay?+
A flat $50 per month for a covered drug, if you qualify and your plan applies prior authorization. That is far below the $1,000-plus list price of a brand-name pen without coverage.
Who qualifies for the Medicare GLP-1 Bridge?+
Part D enrollees with a BMI of 35 or higher qualify on obesity alone. A BMI of 30 to 34.9 qualifies with heart failure, uncontrolled hypertension, or chronic kidney disease. A BMI of 27 to 29.9 qualifies with prediabetes or established cardiovascular disease such as a prior heart attack, stroke, or peripheral artery disease. Confirm your specific eligibility with your plan and Medicare.gov.
What if I do not qualify for the bridge?+
Many people fall outside the criteria: type 2 diabetes as the only indication, sleep apnea or MASH, no Part D plan, or wanting Ozempic specifically. In those cases the realistic affordable route is a self-pay telehealth program that prescribes compounded semaglutide or tirzepatide, commonly from around $129/mo, with no insurance required.
Sources: CMS Medicare GLP-1 Bridge program materials and Medicare.gov; contemporaneous reporting from AARP, NPR, and CNN (June to July 2026). Program details are new and subject to change. This page is informational and is not medical, legal, or insurance advice. Confirm coverage and eligibility with your plan and a licensed professional.